Data from miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer
Tingting Yan(Northwest A&F University), Jing‐Yuan Fang(Shanghai Institute of Hematology), Witold Zgodziński, Qian Liang(Guizhou University), Jia‐Yin Tang(Southwest Jiaotong University), Jinxian Chen(Nanjing Agricultural University), Linlin Ren(Chinese Academy of Sciences), Chaoqin Shen(Sun Yat-sen University), Weiping Zou(University of Michigan), Zhenhua Wang, Qiang Liu(Sun Yat-sen University), Ya-Nan Yu, Ming Zhong(Fudan University), Jie Hong(Changchun University of Science and Technology), Yingxuan Chen(Renji Hospital), Haoyan Chen(Shanghai Jiao Tong University), Danfeng Sun, Ilona Kryczek(University of Michigan), Marek Majewski, Piotr Radwan
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Comprehensive review of targeted therapy for colorectal cancer
|Signal Transduction and Targeted Therapy|2020|1.7k
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
|Current Opinion in Immunology|2013|740
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
|Journal of Clinical Investigation|2018|598